scholarly journals Cancer antigen 125 assessment using carbon quantum dots for optical biosensing for the early diagnosis of ovarian cancer

RSC Advances ◽  
2021 ◽  
Vol 11 (49) ◽  
pp. 31047-31057
Author(s):  
Walaa E. Omer ◽  
Mostafa F. Abdelbar ◽  
Nesma M. El-Kemary ◽  
Naoki Fukata ◽  
Maged A. El-Kemary
Keyword(s):  
Ovarian Cancer ◽  
Quantum Dots ◽  
Early Diagnosis ◽  
Carbon Quantum Dots ◽  
Biological Molecules ◽  
Cancer Antigen 125 ◽  
Cancer Antigen ◽  
Optical Biosensing

Fluorometric quantification of biological molecules is a key feature used in many biosensing studies.

scholarly journals Immunohistochemical Study of CA 125 in Surface Epithelial Tumors of Ovary in Correlation with Serum Levels

2020 ◽  
Vol 7 (7) ◽  
pp. A355-360
Author(s):  
Karishma Pillarisetty ◽  
Savithri Ravindra
Keyword(s):  
Ovarian Cancer ◽  
Ovarian Neoplasms ◽  
Serum Levels ◽  
Tissue Expression ◽  
Epithelial Differentiation ◽  
Ca 125 ◽  
Cancer Antigen 125 ◽  
Cancer Antigen ◽  
Epithelial Tumors ◽  
Wide Range

Background: Ovarian carcinoma is the 4th leading cancer among women in India. Primary ovarian neoplasms exhibit a wide range of histopathological patterns and tumors with epithelial differentiation are most frequent. Among malignant tumors, most common histological type is serous adenocarcinoma whose diagnosis is established in advanced stages of disease in approximately 75% of patients. The most widely used tumor marker in ovarian cancer, often considered “gold standard” is Cancer Antigen125. Cancer Antigen 125 is a high molecular weight glycoprotein which is raised in approximately 90% of patients with advanced epithelial ovarian cancer.   Methods: A 2 year prospective study included 81 cases of ovarian neoplasms with surface epithelial differentiation.  The specimens were fixed in 10% formalin, routinely processed. Sections of 4-5 microns thickness were obtained from the paraffin block and stained with Hematoxylin & Eosin. The tumors were categorised according to WHO classification.  Immunohistochemical analysis of Cancer Antigen 125 was done in all malignant & borderline tumors.   Result: A total of 81 cases were studied. There were 15 cases with elevated serum Cancer Antigen 125 levels. Of these 8 showed positive tissue expression. The sensitivity of serum Cancer Antigen 125 was 68.75% & its specificity was 93.8%.   Conclusion: Serum Cancer Antigen 125 is elevated in ovarian tumors especially in malignant surface epithelial tumors & more commonly in serous cystadenocarcinoma. There was a good correlation between serum levels & tissue expression of Cancer Antigen 125.

scholarly journals The Response of Second Line Chemotherapy Platinum Resistant Ovarian Cancer in Sudan: 2013-2017

2019 ◽  
Author(s):  
Mohammed Altyb Alshykh ◽  
Mohammed Elmujtba Adam Essa ◽  
Yousra Abdelmoniem Suleiman ◽  
Sherihan Mohammed Elkundi Osman ◽  
Mustafa Mohamed Ali Hussein ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Age Group ◽  
Second Line ◽  
Cancer Antigen 125 ◽  
First Line ◽  
Serous Adenocarcinoma ◽  
Cancer Antigen ◽  
Second Line Chemotherapy ◽  
Platinum Resistant ◽  
Line Chemotherapy

Abstract Background Ovarian carcinoma is the fifth leading cause of cancer death worldwide. The tumor mostly associated with variant factors such as advance age, early menstruation and gene association. We aimed to highlight the effectiveness of the second line chemotherapy in the management of ovarian cancer patients in Sudan.Methods The data were collected from the hospital patient’s records for five years period of time, included 62 patients with ovarian cancer who is treated by the second line platinum resistant chemotherapy.Result The peak prevalence of the patients was found in Al-Gazeera state, and the least in Al-Gadarif state. Age group above 55 years was the most affected group. The vast majority of patients showed partially mass disappearing, completes and continue growing tumor respectively. All patients received variant cycles of chemotherapy as fellow 3, 6, 2, 4, 5, 1 cycle respectively. 79.4% of the patients had achieved the normal value of cancer antigen 125 (CA125) levels after the treatment. In 50% of patients the cancer recurred after 1-2 months, 32.2% after 3-4 months and 17.8% after 5-6 months. The serous adenocarcinoma was found to be the most histological type in all the patients and the least two types were observed are cell carcinoma and serous papillary.Conclusion Our findings suggested that, Al-Gazeera state citizens were more vulnerable to resist the first line chemotherapy than others. The Sudanese patients with ovarian cancer may have better response to Gemzar.

scholarly journals Utility of Comprehensive Serum Glycopeptide Spectra Analysis (CSGSA) for the Detection of Early Stage Epithelial Ovarian Cancer

Cancers ◽  
2020 ◽  
Vol 12 (9) ◽  
pp. 2374
Author(s):  
Koji Matsuo ◽  
Kazuhiro Tanabe ◽  
Masaru Hayashi ◽  
Masae Ikeda ◽  
Miwa Yasaka ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Diagnostic Performance ◽  
Screening Tool ◽  
Early Stage ◽  
Cancer Antigen 125 ◽  
Cancer Antigen ◽  
Spectra Analysis ◽  
Human Epididymis Protein 4 ◽  
Human Epididymis

Comprehensive serum glycopeptide spectra analysis (CSGSA) evaluates >10,000 serum glycopeptides and identifies unique glycopeptide peaks and patterns via supervised orthogonal partial least-squares discriminant modeling. CSGSA was more accurate than cancer antigen 125 (CA125) or human epididymis protein 4 (HE4) for detecting early stage epithelial ovarian cancer. Combined CSGSA, CA125, and HE4 had improved diagnostic performance. Thus, CSGSA may be a useful screening tool for detecting early stage epithelial ovarian cancer.

Rectosigmoidectomy and Douglas Peritonectomy in the Management of Serosal Implants in Advanced-Stage Ovarian Cancer Surgery: Survival and Surgical Outcomes

2018 ◽  
Vol 28 (9) ◽  
pp. 1699-1705 ◽  
Author(s):  
Selçuk Erkilinç ◽  
Volkan Karataşli ◽  
Batuhan Demir ◽  
İlker çakir ◽  
Behzat Can ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Overall Survival ◽  
Surgical Outcomes ◽  
Cancer Surgery ◽  
Advanced Stage ◽  
Cancer Antigen 125 ◽  
Debulking Surgery ◽  
Cancer Antigen ◽  
Colon Wall ◽  
Disease Free

ObjectiveThis study aimed to evaluate the outcomes of rectosigmoid resection (RR) and Douglas peritonectomy (DP) on postoperative complications and survival in advanced-stage ovarian cancer surgery.Methods/MaterialsPatients who underwent optimal cytoreductive surgery including RR and DP between January 2007 and January 2013 were included. Patients with deeper invasion into the muscularis and mucosal layer reported in pathology results and colon wall injury necessitating suturing or resection suggesting invasion of implants into the colon wall were excluded. The decision for RR or DP was made according to the surgical team and patients’ preference. Resections were performed with the suspicion of colon wall invasion. The collected data were age, previous operations, preoperative cancer antigen 125 and albumin levels, surgical procedures, duration of surgery, tumor histology, recurrence, hyperthermic intraperitoneal chemotherapy, and length of hospital stay. Kaplan-Meir survival estimates were calculated and compared between the groups using the log-rank test. Cox proportional models were built to evaluate factors that affected disease-free and overall survival.ResultsAge, body mass index, preoperative cancer antigen 125 levels, albumin levels, and amount of ascites were similar between the groups. Neoadjuvant chemotherapy followed by interval debulking surgery was performed in 15% of both groups. End colostomy was performed in 23.7% of the RR group, and only 5.08% of the patients underwent diverting ileostomy procedures. There was no significant difference in terms of surgical complications between the groups. Recurrence occurred in the RR and DP groups at rates of 42% and 47%, respectively. Only primary debulking surgery had an effect on overall survival (odds ratio, 0.5; 95% confidence interval, 0.31–0.88). Overall survival and disease-free survival were similar in the RR and DP groups.ConclusionsDouglas peritonectomy showed similar survival and surgical outcomes to RR and provided shorter hospital stay and earlier admission to chemotherapy in the management of serosal implants during advanced-stage ovarian cancer surgery.

Sign in / Sign up

Export Citation Format

Share Document